This update serves to clarfy the fact that fourth-quarter profit increased 11.5 percent, not 40 percent as originally reported.
Total receipts for the Biosciences unit during the three months ended Dec. 31, 2005, increased to $199.5 million from $180.8 million year over year. Around $85 million of that was from sales in the
BD attributed the growth to strong sales of reagents and research instruments, particularly research analyzers and sorters.
BD said company-wide fiscal first-quarter revenue increased 10 percent to $1.4 billion, though "unfavorable" foreign-currency translations cost the firm 1 percent in lost growth.
Spending on R&D increased 11.7 percent in the quarter, jumping to $69.3 million from $62 million year over year, BD said.
The company said profits increased 11.5 percent to $217.9 million, or $.88 per basic share, from $195.4 million, or $.78 per basic share, during the same period last year.
BD did not break out its balance sheet for the quarter.